Anti-CD22 Antibodies with Internalization and Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CD22 therapies, such as epratuzumab, lack direct anti-proliferative effects and complement-dependent cytotoxicity, and there is a need for additional reagents that can effectively target CD22+ B cell malignancies and autoimmune disorders with enhanced mechanisms like internalization, antibody-dependent cellular cytotoxicity, and cytotoxin conjugation.
Innovation Solution
Development of isolated monoclonal antibodies with specific heavy and light chain variable region CDR sequences that bind to human CD22 with high affinity, facilitating internalization, antibody-dependent cellular cytotoxicity, and cytotoxin-mediated cell death, while avoiding direct anti-proliferative effects and complement-dependent cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If epratuzumab is used as anti-CD22 therapy, then CD22 binding is achieved, but direct anti-proliferative effects and complement-dependent cytotoxicity are lacking
Solution Approach 1:
The patent modifies the antibody molecule through parameter changes in the complementarity determining regions (CDRs), specifically changing the amino acid sequences in CDR1, CDR2, and CDR3 regions. This allows the antibody to maintain high affinity binding to CD22 while acquiring new functional properties including direct anti-proliferative effects and complement-dependent cytotoxicity, thereby resolving the contradiction between binding capability and therapeutic mechanism diversity
Solution Approach 2:
The invention creates a composite functional profile by combining multiple mechanisms of action within a single antibody molecule. The antibody simultaneously exhibits binding to CD22, internalization, antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct anti-proliferative effects, effectively creating a multi-functional therapeutic agent that addresses the limitation of single-mechanism therapies
2Adaptability or versatility
If additional anti-CD22 reagents are developed, then treatment options are expanded, but development complexity increases
Solution Approach 1:
The patent segments the antibody molecule into distinct functional regions with specific CDR sequences that can be independently optimized. By defining specific amino acid sequences for CDR1, CDR2, and CDR3, the invention allows modular development and characterization of individual functional elements, simplifying the overall development process while expanding treatment options
Solution Approach 2:
The invention uses copying of functional motifs from successful antibody designs. The patent incorporates CDR sequences that have been shown to mediate specific functions (binding, internalization, cytotoxicity) and replicates these functional patterns to create new anti-CD22 reagents with predictable and reproducible therapeutic effects, thereby reducing development complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies exhibit high affinity binding to CD22, internalize into CD22+ cells, mediate antibody-dependent cellular cytotoxicity, enhance cell death upon B cell receptor stimulation, and inhibit CD22-expressing cell growth when conjugated with cytotoxins, providing effective treatment options for B cell malignancies and autoimmune disorders.
Implementation Method 1
The antibodies of the invention exhibit high affinity binding to CD22
Implementation Method 2
the ability to internalize into CD22+ cells
Implementation Method 3
the ability to mediate antibody dependent cellular cytotoxicity (ADCC), the ability to enhance cell death of Ramos cells induced by B cell receptor (BCR) stimulation
Implementation Method 4
inhibits growth of CD22-expressing cells in vivo when conjugated to a cytotoxin
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody- partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.